Fusion proteins and their uses

A TDP-43 protein degeneration model using a fusion protein that responds to stimulation addresses the inadequacies of existing models by accurately simulating disease states, facilitating the development of therapeutic drugs for ALS and FTLD.

JP7587822B2Active Publication Date: 2024-11-21INTER UNIV RES INST RES ORG OF INFORMATION & SYST
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020550350
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-01
Filing Date
2019-09-26
Publication Date
2024-11-21
Estimated Expiration
2039-09-26

AI Technical Summary

Technical Problem

Existing models for TDP-43 protein degeneration, such as ALS and FTLD, do not accurately reflect the disease state due to the absence of mutations in the TDP-43 gene and overexpression, leading to inadequate representation of pathological features.

Method used

Development of a TDP-43 protein degeneration model using a fusion protein that forms dimers or multimers in response to stimulation, along with a gene, vector, and non-human animal models to simulate pathological conditions, allowing for the creation of a screening method and device for therapeutic or prophylactic drug selection.

Benefits of technology

The model effectively reflects the pathology of TDP-43 protein degeneration, enabling the identification of candidate substances for preventing or treating diseases like ALS and FTLD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587822000001
    Figure 0007587822000001
  • Figure 0007587822000002
    Figure 0007587822000002
  • Figure 0007587822000003
    Figure 0007587822000003
Patent Text Reader

Abstract

A fusion protein comprising any one of the following proteins (A) to (C) and a tag protein that dimerizes or multimerizes in response to a stimulus: (A) a protein consisting of the amino acid sequence represented by SEQ ID NO: 1; (B) a protein having an amino acid sequence having 70% or more identity to the amino acid sequence represented by SEQ ID NO: 1 and having the ability to form aggregates; (C) A protein having an amino acid sequence in which one or several amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 1 and having the ability to form aggregates.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a fusion protein and its use. This application claims priority based on Japanese Patent Application No. 2018-186569, filed on October 1, 2018, the contents of which are incorporated herein by reference. [Background technology]

[0002] In the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), inclusions composed mainly of the aggregated RNA-binding protein TDP-43 (TAR DNA-binding protein of 43 kDa) are known to accumulate in the cytoplasm of neurons in the brain and spinal cord that are lost due to degeneration. ALS and FTLD are collectively referred to as TDP-43 protein degeneration diseases.

[0003] Based mainly on the accumulation of inclusion bodies mainly composed of TDP-43, it is predicted that TDP-43 is closely involved in the onset and progression of TDP-43 protein deficiency, and it is expected that a treatment for TDP-43 protein deficiency may be developed from the viewpoints of manipulating the function of TDP-43, inhibiting TDP-43 aggregation, and removing TDP-43 aggregates.

[0004] As described above, accumulation of TDP-43 aggregates is one of the pathological characteristics of TDP-43 proteinopathy, and a pathological model reflecting such a characteristic has been proposed (see, for example, Patent Document 1). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2014-171425 A Summary of the Invention [Problem to be solved by the invention]

[0006] However, because mutations in the TDP-43 gene and overexpression of the TDP-43 protein are not observed in most cases of ALS, there was concern that the phenotype of a pathological model manifested by introducing amino acid substitution mutations into TDP-43 and overexpressing the mutant TDP-43 thus produced, as in the pathological model described in Patent Document 1, does not necessarily reflect the pathological condition.

[0007] The present invention has been made in consideration of the above circumstances, and provides a TDP-43 protein degeneration model that reflects the pathology of TDP-43 protein degeneration, a fusion protein, a gene, a vector, a cell, and a non-human animal for creating such a model, and a screening method, a screening kit, and a screening device using such a model. [Means for solving the problem]

[0008] The inventors investigated the association state and intracellular localization of the TDP-43 protein and discovered a modified TDP-43 protein that behaves in vivo in a manner closer to the pathophysiological state, thereby completing the present invention.

[0009] That is, the present invention includes the following aspects. [1] A fusion protein comprising any one of the following proteins (A) to (C) and a tag protein that dimerizes or multimerizes in response to a stimulus: (A) a protein consisting of the amino acid sequence represented by SEQ ID NO:1; (B) a protein having an amino acid sequence having 70% or more identity to the amino acid sequence represented by SEQ ID NO:1 and having the ability to form aggregates; (C) A protein having an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted or added in the amino acid sequence shown in SEQ ID NO:1 and having the ability to form aggregates. [2] The fusion protein according to [1], further comprising a labeling protein. [3] A gene encoding the fusion protein described in [1] or [2]. [4] A vector comprising the gene described in [3]. [5] A cell comprising the fusion protein described in [1] or [2], the gene or its transcription product described in [3], or the vector described in [4]. [6] A cell described in [5], in which the expression of the tardp gene or a homolog thereof, and the tardpl gene or a homolog thereof is suppressed or lost, or the function of the Tardbp protein or a homolog thereof, and the Tardbpl protein or a homolog thereof is suppressed or lost. [7] A non-human animal comprising the fusion protein described in [1] or [2], the gene or its transcription product described in [3], or the vector described in [4]. [8] A non-human animal according to [7], in which the expression of the tardp gene or a homolog thereof, and the tardpl gene or a homolog thereof is suppressed or lost, or the function of the Tardbp protein or a homolog thereof, and the Tardbpl protein or a homolog thereof is suppressed or lost. [9] A TDP-43 proteinopathy model comprising a cell according to [5] or [6], or a non-human animal according to [7] or [8], in which the protein forms a dimer or multimer in response to a stimulus.

[10] A TDP-43 protein degeneration model according to [9], which is an amyotrophic lateral sclerosis or frontotemporal lobar degeneration model.

[11] A screening method comprising contacting or administering a test substance to a cell described in [5] or [6], or a non-human animal described in [7] or [8], in the presence of a stimulus, and selecting a candidate substance useful for preventing or treating TDP-43 protein degeneration.

[12] A screening kit for a preventive or therapeutic drug for TDP-43 protein degeneration, comprising the cell described in [5] or [6], or the non-human animal described in [7] or [8].

[13] An apparatus for screening preventive or therapeutic drugs for TDP-43 protein degeneration, comprising a cell according to [5] or [6], or a non-human animal according to [7] or [8], a well plate containing either of these, and a light irradiation device. Effect of the Invention

[0010] According to the present invention, a model of TDP-43 proteinopathy that reflects the pathology of TDP-43 proteinopathy can be provided. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 is a schematic diagram showing an example of a screening device according to an embodiment of the present invention. [Diagram 2] FIG. 1 is a schematic diagram showing an example of the fusion protein of the present invention. [Diagram 3] Photographs of wild-type zebrafish and zebrafish in which the tardp gene and the tardpl gene have been knocked out (tardbp - / -, tardbpl - / -). [Figure 4] 1 is a graph showing the restoration of blood circulation in the heart of zebrafish (tardbp − / −, tardbpl − / −) by optoTDP-43. [Diagram 5] This is an observation result of the translocation of TDP-43 protein to the cytoplasm upon exposure to blue light. [Figure 6] This is an observation result of translocation of TDP-43 protein to the cytoplasm upon blue light irradiation in zebrafish expressing the fusion protein specifically in spinal cord neurons. [Figure 7] This shows the results of observing axonal elongation upon blue light irradiation in zebrafish in which the fusion protein was specifically expressed in spinal cord neurons. [Figure 8A] Observation of axonal branches in zebrafish in which optoTDP-43 is expressed exclusively in spinal motor neurons. [Figure 8B] 13 is a graph showing the number of axonal collateral branches in zebrafish expressing optoTDP-43 exclusively in spinal motor neurons. [Figure 8C] Observational results showing pre- and postsynaptic localization of optoTDP-43 in zebrafish expressing it exclusively in spinal motor neurons. [Figure 9A]These are observational results showing that blue light irradiation induces optoTDP-43 aggregation in the cytoplasm in zebrafish, which express optoTDP-43 in almost all motor neurons. [Figure 9B] These are observational results showing that blue light irradiation induces cytoplasmic aggregation of optoTDP-43 and endogenous TDP-43 in zebrafish motor neurons that express optoTDP-43 in almost all of their motor neurons. [Figure 10A] This is an observational result showing that blue light irradiation causes defective formation of the swim bladder in zebrafish expressing optoTDP-43A315T in almost all motor neurons. [Figure 10B] 13 is a graph showing the percentage of swim bladder hypoplasia induced by blue light irradiation in zebrafish expressing optoTDP-43A315T in almost all motor neurons. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] <<Fusion protein>> The fusion protein of the present invention comprises a tag protein that dimerizes or multimerizes in response to a stimulus with any one of the following proteins (A) to (C): (A) a protein consisting of the amino acid sequence represented by SEQ ID NO:1; (B) a protein having an amino acid sequence having 70% or more identity to the amino acid sequence represented by SEQ ID NO:1 and having the ability to form aggregates; (C) A protein having an amino acid sequence in which one or several amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO:1 and having the ability to form aggregates.

[0013] The amino acid sequence represented by SEQ ID NO: 1 is the amino acid sequence of the zebrafish Tardbp protein. The zebrafish Tardbp protein is a homologue of the human TDP-43 protein. The amino acid sequence of the human TDP-43 protein is represented by SEQ ID NO: 2. In zebrafish, there are two homologues, Tardbp and Tardbpl, and the amino acid sequence of the zebrafish Tardbpl protein is shown in SEQ ID NO:3. The zebrafish Tardbp protein and human TDP-43 protein share 73% identity at the amino acid level, and the zebrafish Tardbp protein and zebrafish Tardbpl protein share 78% identity at the amino acid level. Any one of the proteins (A) to (C) also includes a protein having an amino acid sequence represented by SEQ ID NO: 1 to 3.

[0014] In (B), the identity is more preferably 75% or more, further preferably 80% or more, particularly preferably 85% or more, and most preferably 90% or more.

[0015] The number of deleted, substituted, inserted or added amino acids in (C) is preferably 1 to 120, more preferably 1 to 60, even more preferably 1 to 20, particularly preferably 1 to 10, and most preferably 1 to 5.

[0016] In the present invention, "aggregate forming ability" refers to the ability to form amorphous aggregated cellular components detectable using an optical microscope such as a confocal laser microscope, or cellular components detected as an insoluble fraction in a cell extract, which are predicted to be formed via an intermediate stage of the formation of dimers or higher multimers.

[0017] The tag protein that dimerizes or multimerizes in response to a stimulus refers to a protein that contains a functional domain of a protein that forms a dimer or multimer under irradiation with light or in the presence of a compound. Examples of sets of tagged proteins that form heterodimers under light irradiation include the set of PhyB and PIF, the set of FKF1 and GI, the set of CRY2 and CIB1, the set of UVR8 and COP1, the set of VVD and WC1, the set of PhyB and CRY1, and the set of RpBphP1 and RpPpsR2. Examples of tag proteins that form homodimers under light irradiation include UVR8, EL222, bPac, RsLOV, PYP, H-NOXA, YtvA, NifL, FixL, RpBphP1, and CRY2. Examples of sets of tagged proteins that form heterodimers in the presence of a compound include a set of FKBP (FK506-binding protein) and FRB (FKBP12-rapamycin associated protein 1 fragment) in the presence of rapamycin, a system using gibberellin (a compound) and its binding protein (GAI / GID1), a system using fusicoccin (a compound) and its binding protein (CT52M1 / T14-3-3cΔC-M2), a system using abscisic acid (a compound) and its binding protein (PYL / ABI), and a system using rCD1 / FK506 (a compound) and its binding protein (FKBP / SNAP).

[0018] Among the above-mentioned tag proteins, for example, there is a mutant fragment of cryptochrome CRY2 derived from Arabidopsis thaliana that has the activity of absorbing blue light and self-associating. Examples of mutant fragments of cryptochrome CRY2 include proteins having any one of the following amino acid sequences (D) to (F). (D) a protein consisting of the amino acid sequence represented by SEQ ID NO:4; (E) a protein having an amino acid sequence having 80% or more identity to the amino acid sequence represented by SEQ ID NO: 4 and having the activity of absorbing blue light and self-associating; (F) A protein having an amino acid sequence in which one or several amino acids are deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 4, and having an activity of absorbing blue light and self-associating.

[0019] In (E), the identity is more preferably 85% or more, further preferably 90% or more, and particularly preferably 95% or more.

[0020] The number of deleted, substituted, inserted or added amino acids in (F) is preferably 1 to 100, more preferably 1 to 60, even more preferably 1 to 20, particularly preferably 1 to 10, and most preferably 1 to 5.

[0021] The fusion protein of the present invention preferably further contains a labeling protein. The labeling protein is not particularly limited as long as it can confirm the expression of the fusion protein in cells. For example, the labeling protein may be an antibody epitope sequence or a fluorescent protein, and from the viewpoint of observing living cells, a fluorescent protein is preferable. Examples of fluorescent proteins include green fluorescent protein (GFP), red fluorescent protein (RFP), cyan fluorescent protein (CFP), and yellow fluorescent protein (YFP). An example of a fusion protein containing a labeled protein is a protein consisting of the amino acid sequence shown in SEQ ID NO:5.

[0022] <<Gene encoding the fusion protein>> The gene of the present invention is a gene encoding the above-mentioned fusion protein of the present invention. Such genes include those consisting of any one of the following base sequences (G) to (K) and including a gene encoding a protein capable of forming aggregates and a gene encoding a tag protein that dimerizes or multimerizes in response to a stimulus. (G) a base sequence represented by SEQ ID NO: 6; (H) a base sequence in which one or several bases are deleted, substituted, inserted, or added in the base sequence represented by SEQ ID NO: 6; (I) a base sequence having an identity of 70% or more, preferably 75% or more, more preferably 80% or more, even more preferably 85% or more, and particularly preferably 90% or more, to the base sequence represented by SEQ ID NO:6; (J) a nucleotide sequence capable of hybridizing under stringent conditions with a gene having a nucleotide sequence complementary to the gene having the nucleotide sequence represented by SEQ ID NO:6. (K) Degenerate isomers of the base sequences (G) to (J)

[0023] In (H), the number of bases that may be deleted, substituted, inserted or added is preferably 1 to 370, more preferably 1 to 180, even more preferably 1 to 60, particularly preferably 1 to 130, and most preferably 1 to 15.

[0024] In (J), "stringent conditions" refers to conditions in which hybridization is carried out by incubation for several hours to overnight at 55 to 70°C in a hybridization buffer consisting of 5xSSC (20xSSC composition: 3M sodium chloride, 0.3M citric acid solution, pH 7.0), 0.1% by weight N-lauroyl sarcosine, 0.02% by weight SDS, 2% by weight blocking reagent for nucleic acid hybridization, and 50% formamide. The washing buffer used for washing after incubation is preferably a 1xSSC solution containing 0.1% by weight SDS, more preferably a 0.1xSSC solution containing 0.1% by weight SDS.

[0025] For amino acids other than methionine and tryptophan, multiple codons correspond to one amino acid. This is called the degeneracy of the genetic code. In (K), a degenerate isomer of a base sequence means another base sequence that corresponds to the amino acid coded for by a certain base sequence.

[0026] Examples of genes encoding tag proteins that dimerize or multimerize in response to a stimulus include genes encoding the above-mentioned proteins, such as mutant fragments of genes encoding cryptochromes derived from Arabidopsis thaliana that have the activity of absorbing blue light and self-associating. Examples of mutant fragments of genes encoding cryptochromes include genes that consist of any one of the following base sequences (L) to (P) and encode proteins that have the activity of absorbing blue light and self-associating. (L) a base sequence represented by SEQ ID NO: 7; (M) a base sequence in which one or more bases are deleted, substituted, inserted, or added in the base sequence represented by SEQ ID NO: 7; (N) a base sequence having an identity of 80% or more, preferably 85% or more, more preferably 90% or more, and particularly preferably 95% or more, to the base sequence represented by SEQ ID NO: 7; (O) a nucleotide sequence capable of hybridizing under stringent conditions with a gene having a nucleotide sequence complementary to the gene having the nucleotide sequence represented by SEQ ID NO: 7. (P) A degenerate isomer of the base sequence of (L) to (O)

[0027] Furthermore, an example of a gene encoding a fusion protein containing a labeling protein is one consisting of the base sequence shown in SEQ ID NO:8.

[0028] <<vector>> The vector of the present invention contains the above-mentioned gene of the present invention. The vector is not particularly limited, and may be a conventionally known vector such as a plasmid vector, a virus vector, etc. Examples of the plasmid vector include vectors having promoters for expression in animal cells, such as a CAG promoter, an EF1α promoter, an SRα promoter, an SV40 promoter, an LTR promoter, a CMV (cytomegalovirus) promoter, and an HSV-tk promoter. Examples of viral vectors include retroviral vectors, adenoviral vectors, adeno-associated viral vectors, vaccinia viral vectors, lentiviral vectors, herpes viral vectors, alphaviral vectors, EB viral vectors, papilloma viral vectors, and foamy viral vectors.

[0029] <<Cells and non-human animals>> The cell of the present invention comprises the fusion protein of the present invention, or the gene of the present invention or a transcription product thereof, or the vector of the present invention.

[0030] Examples of organisms from which the cells of the present invention can be derived include mammals such as humans, monkeys, dogs, cats, rabbits, pigs, cows, mice, rats, and hamsters. Further examples include vertebrates in general, such as fish, amphibians, birds, and reptiles. Further examples include invertebrates such as fruit flies, yeast, and the like.

[0031] Hosts used for the cells of the present invention include neural cells such as glial cells, neuronal cells, oligodendrocytes, microglia, and astrocytes.

[0032] Alternatively, the host may be a neural cell differentiated from a stem cell. A stem cell is a cell that has both the ability to replicate itself and the ability to differentiate into cells of multiple lineages. Examples of stem cells include embryonic stem cells (ES cells), embryonic tumor cells, embryonic germline stem cells, induced pluripotent stem cells (iPS cells), neural stem cells, hematopoietic stem cells, mesenchymal stem cells, hepatic stem cells, pancreatic stem cells, muscle stem cells, germline stem cells, intestinal stem cells, cancer stem cells, and hair follicle stem cells.

[0033] The method for introducing the fusion protein of the present invention, the gene of the present invention or a transcription product thereof, or the vector of the present invention into a host can be a method suitable for the living cells used, and examples of such methods include electroporation, heat shock, calcium phosphate, lipofection, DEAE-dextran, microinjection, particle gun, methods using viruses, and methods using commercially available transfection reagents such as FuGENE (registered trademark) 6 Transfection Reagent (manufactured by Roche), Lipofectamine 2000 Reagent (manufactured by Invitrogen), Lipofectamine LTX Reagent (manufactured by Invitrogen), and Lipofectamine 3000 Reagent (manufactured by Invitrogen).

[0034] Furthermore, the non-human animal of the present invention comprises the above-mentioned fusion protein of the present invention, or the above-mentioned gene of the present invention or a transcription product thereof, or the above-mentioned vector of the present invention. The non-human animal is preferably a mammal or a fish. The non-human mammal includes a mouse, a rat, a guinea pig, a hamster, a rabbit, a goat, a pig, a dog, and a cat, and is preferably a rodent such as a mouse or a rat. The fish is preferably a zebrafish.

[0035] As described later in the Examples, it has been confirmed that the fusion protein of the present invention can complement the function of wild-type TDP-43. Therefore, from the viewpoint of being closer to physiological conditions, it is preferable that the cell or non-human animal of the present invention has suppressed or lost expression of the tardp gene or its homolog, and the tardpl gene or its homolog, or has suppressed or lost function of the Tardbp protein or its homolog, and the Tardbpl protein or its homolog.

[0036] The phrase "the functions of the Tardbp protein and the Tardbpl protein are suppressed" refers to a state in which the original functions of the Tardbp protein and the Tardbpl protein are partially lost. The term "loss of function of Tardbp protein and Tardbpl protein" refers to a state in which the original functions of Tardbp protein and Tardbpl protein are completely lost.

[0037] The inhibition or loss of function of the Tardbp protein and the Tardbpl protein can also occur by inhibiting or losing the expression of the tardp gene and the tardpl gene.

[0038] Suppression of the expression of the tardp gene and the tardpl gene means that the amounts of the tardp gene product and the tardpl gene product are suppressed in the cells or animals of the present invention compared to wild-type control cells or animals. Suppression of expression of the tardp gene and the tardpl gene can be achieved by introducing a nucleic acid sequence that induces expression of RNAi-inducing nucleic acid, antisense nucleic acid, aptamer, ribozyme, etc. against the tardp gene and the tardpl gene into a cell or animal, and performing gene knockdown, etc.

[0039] Loss of expression of the tardp and tardpl genes refers to the loss of the tardp and tardpl gene products in a cell or animal. Loss of function of the gene products, Tardbp protein and Tardbpl protein, can be caused, for example, by introducing a mutation into the tardp gene and the tardpl gene, thereby disrupting the tardp gene and the tardpl gene. Mutations can be produced by partial or total deletion, substitution, insertion of any sequence, etc., in the tardp gene and the tardpl gene, or in the expression regulatory regions of these genes. These mutations can be introduced using techniques such as treatment with mutagens, ultraviolet irradiation, gene targeting using homologous recombination techniques, gene knockout, conditional knockout using the Cre-loxP system, etc. For gene targeting and gene knockout, genome editing techniques may be used.

[0040] The cells or non-human animals of the present invention are useful as models of TDP-43 protein degeneration, since the protein forms dimers or multimers in response to a stimulus and forms aggregates in the cytoplasm. Examples of the TDP-43 protein degeneration models include amyotrophic lateral sclerosis, frontotemporal lobar degeneration models, Parkinson's disease models, and Alzheimer's disease models, and amyotrophic lateral sclerosis or frontotemporal lobar degeneration models are preferred.

[0041] <<Screening method>> The screening method of the present invention is a method of contacting or administering a test substance to a cell of the present invention or a non-human animal of the present invention in the presence of a stimulus, and selecting a candidate substance useful for preventing or treating TDP-43 protein degeneration.

[0042] For example, the compound library is added to a medium, and blue light is applied to cells or zebrafish to examine the effect on cell proliferation or zebrafish growth. More specifically, for example, the cells of the present invention are seeded on a well plate, or zebrafish are introduced as the non-human animal of the present invention, and cultured or raised for about 1 to 10 days in the presence of the compound library while promoting dimerization of TDP-43 protein under blue light irradiation. Thereafter, the number of live cells is analyzed, for example, by color development due to reduction of tetrazolium salt. As the tetrazolium salt, commercially available 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and the like can be used. For zebrafish, the live or dead status and activity state of the zebrafish can be confirmed. Cytotoxicity gradually occurs due to dimerization of TDP-43 protein, and a compound that maintains or enhances cell proliferation is a candidate for a preventive or therapeutic agent for TDP-43 protein degeneration.

[0043] <<Screening kit>> The screening kit for a preventive or therapeutic drug for TDP-43 protein degeneration of the present invention is a kit comprising the cell of the present invention or the non-human animal of the present invention. The kit of the present invention may contain, in addition to the cell of the present invention or the non-human animal of the present invention, things necessary for screening, such as a multi-well plate.

[0044] <<Screening equipment>> The device for screening a preventive or therapeutic drug for TDP-43 protein degeneration of the present invention is an apparatus equipped with the cell of the present invention or the non-human animal of the present invention, a well plate containing either of them, and a light irradiation device.

[0045] 1 is a schematic diagram showing an example of the screening device of the present embodiment. Each component of the screening device of the present embodiment will be described in detail with reference to FIG. The screening device 100 shown in FIG. 1 includes a zebrafish model 1 with TDP-43 proteinopathy (hereinafter, zebrafish 1), a well plate 2, a control unit 3, and a light irradiation device 4. Zebrafish1 expresses in vivo a fusion protein containing a mutant fragment of the cryptochrome CRY2 from Arabidopsis thaliana, which has blue light absorbing and self-associating activity, and the zebrafish Tardbp protein. Each well of well plate 2 contains a compound from a compound library, and a zebrafish 1 with a length of 3 mm is swimming in the water filled in the well. The light irradiation device 4 irradiates the wells with blue light based on a command from the control unit 3 . Zebrafish 1 are cultured for about 1 to 10 days in the presence of a compound library while being exposed to blue light to promote dimerization of Tardbp protein. The formation of dimers or multimers of Tardbp protein gradually leads to neurotoxicity, and compounds present in wells where zebrafish 1 are growing without affecting their activity are candidates for preventive or therapeutic agents for TDP-43 protein degeneration.

[0046] Although not shown, the screening device 100 may also be equipped with a microscope for observing the zebrafish 1. In another embodiment, a cultured cell model of TDP-43 protein degeneration may be used instead of zebrafish. EXAMPLES

[0047] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.

[0048] [Construction of fusion protein expression system] We created a gene construct that expresses a fusion protein in which a mutant fragment (CRY2olig) of the cryptome derived from Arabidopsis thaliana, which has the activity of self-associating when it absorbs blue light, and a red fluorescent protein (mRFP1) are added to the zebrafish-derived TDP-43 (Tardbp) protein (see Figure 2). This fusion protein is called optoTDP-43. The amino acid sequence of optoTDP-43 is shown in SEQ ID NO:5, and the base sequence of the gene encoding optoTDP-43 is shown in SEQ ID NO:8.

[0049] [Functional assay of fusion proteins] We created zebrafish (tardbp - / -, tardbpl - / -) in which the tardp and tardpl genes were knocked out, and confirmed that they exhibited a phenotype of impaired blood circulation. The mRNA of the gene encoding the zebrafish-derived TDP-43 (Tardbp) protein and the mRNA of the gene encoding optoTDP-43 were injected into these double knockout zebrafish. In zebrafish introduced with the mRNA of the gene encoding TDP-43 (Tardbp) and in zebrafish introduced with the mRNA of the gene encoding optoTDP-43 and raised in the dark, blood circulation was restored. However, in zebrafish introduced with the mRNA of the gene encoding optoTDP-43 and raised under blue light irradiation, no recovery of blood circulation in the heart was observed (see Figure 4). This confirmed that the constructed optoTDP-43 has the function of TDP-43 and that its function can be controlled by the presence or absence of blue light irradiation.

[0050] [Observation of TDP-43 protein translocation to the cytoplasm upon blue light irradiation] The above double knockout zebrafish (tardbp - / -, tardbpl - / -) were introduced with mRNA of the gene encoding optoTDP-43, and were continuously irradiated with blue light. The intracellular localization of optoTDP-43 in muscle cells was observed using mRFP1 fluorescence as an indicator. As shown in Figure 5, the translocation of optoTDP-43 to the cytoplasm was confirmed in a time-dependent manner. Furthermore, the red fluorescence in the cytoplasm showed dots, confirming that optoTDP-43 formed aggregates.

[0051] [Observation of TDP-43 protein translocation to the cytoplasm and axonal elongation upon blue light irradiation in zebrafish expressing the fusion protein specifically in spinal motor neurons] By introducing a bacterial artificial chromosome (BAC) containing optoTDP-43 under the promoter of the mnr2b gene into the wild type, we constructed zebrafish in which optoTDP-43 is expressed only in the spinal motor neurons (see Protocadherin-Mediated Cell Repulsion Controls the Central Topography and Efferent Projections of the Abducens Nucleus. Asakawa K, Kawakami K. Cell Reports. 2018 24:p1562-1572.). We continuously irradiated the zebrafish with blue light and observed the translocation of optoTDP-43 in the spinal motor neurons using the fluorescence of mRFP1 as an indicator. As shown in Figure 6, the amount of optoTDP-43 localized in the nucleus decreased in a time-dependent manner, and it was confirmed that optoTDP-43 had translocated to the cytoplasm. Zebrafish in which the translocation of optoTDP-43 to the cytoplasm was promoted by irradiation with blue light were reared again under dark conditions, and the axonal growth was observed afterwards. The axonal growth was inhibited (see Figure 7). Therefore, it was confirmed that the transient promotion of the translocation of optoTDP-43 to the cytoplasm causes toxicity to spinal motor neurons.

[0052] [Observation of neuromuscular synapses formed by blue light irradiation in zebrafish expressing fusion proteins specifically in spinal motor neurons] Furthermore, using zebrafish expressing optoTDP-43 only in spinal motor neurons, we irradiated 56-hour-old larvae in which motor neuron arborization had already been formed with blue light for 3 hours and then reared them in the dark for 13 hours to observe changes in axon arborization and neuromuscular synapses. As shown in Figure 8A, the number of axon arborizations was counted. The results are shown in Figure 8B.

[0053] As shown in Figure 8B, the rate at which the number of axon terminals decreased was increased in motor neurons that experienced optical stimulation with optoTDP-43. In addition, when the localization of presynapses and postsynapses was confirmed, it was confirmed that the collapse of neuromuscular synapses was also promoted (see Figure 8C).

[0054] [Observation of optoTDP-43 and TDP-43 aggregation by blue light irradiation in zebrafish expressing fusion proteins specifically in motor neurons] Using the BAC line with optoTDP-43 introduced above, we constructed a zebrafish line expressing optoTDP-43 in almost all motor neurons, raised it on a blue LED light panel, and observed the aggregation of optoTDP-43 and TDP-43. As shown in Figure 9A, long-term light stimulation was confirmed to induce the aggregation of optoTDP-43 in the cytoplasm. As shown in Figure 9B, endogenous TDP-43 was also involved in the aggregation, confirming the propagability of the aggregation.

[0055] [Observation of motor impairment induced by blue light exposure in zebrafish expressing a mutant (A315T) fusion protein specifically in motor neurons] optoTDP-43 containing the A315T mutation found in familial ALS A315TWe established a line expressing optoTDP-43 in almost all motor neurons and observed changes in motility due to blue light irradiation. As shown in Figure 10A, the introduction of the A315T mutation resulted in defective formation of the swim bladder. As shown in Figure 10B, optoTDP-43 was more effective than optoTDP-43 in terms of motility. A315T In the control group, an increase in the formation of the swim bladder was confirmed. Since the formation of the swim bladder is necessary for the development of normal motility, it can be said that light exposure induces motility disorders.

[0056] In this way, it has been confirmed that optoTDP-43 can be widely used in a wide range of applications, from cultured cells to non-human animals, and can be applied to reproduce pathological conditions that are controlled in a temporal and spatial manner and to develop drugs that alleviate TDP-43 toxicity. [Industrial Applicability]

[0057] The present invention can provide a TDP-43 proteinopathy model that reflects the pathology of TDP-43 proteinopathy.

Claims

1. A zebrafish in which the expression of the tardp gene and the tardpl gene is suppressed or lost, or the function of the Tardbp protein and the Tardbpl protein is suppressed or lost, A zebrafish comprising a fusion protein comprising any one of the following proteins (A) to (C) and a tag protein that dimerizes or multimerizes in response to a stimulus: (A) a protein consisting of the amino acid sequence represented by SEQ ID NO:1; (B) a protein having an amino acid sequence having 90% or more identity to the amino acid sequence represented by SEQ ID NO:1 and having the ability to form aggregates; (C) A protein having an amino acid sequence in which 1 to 20 amino acids have been deleted, substituted, inserted, or added in the amino acid sequence represented by SEQ ID NO: 1 and having the ability to form aggregates.

2. The zebrafish of claim 1 , wherein the fusion protein further comprises a marker protein.

3. The zebrafish of claim 1 or 2, wherein the fusion protein is expressed specifically in motor neurons.

4. The zebrafish according to any one of claims 1 to 3, wherein the fusion protein is expressed specifically in spinal motor neurons.

5. The zebrafish according to any one of claims 1 to 4, wherein the protein is a protein consisting of an amino acid sequence represented by SEQ ID NO:1, the amino acid sequence having an A315T mutation.

6. A screening method comprising contacting or administering a test substance to the zebrafish according to any one of claims 1 to 5 in the presence of a stimulus, and selecting a candidate substance useful for preventing or treating TDP-43 protein degeneration.

7. The screening method according to claim 6, wherein in selecting a candidate substance, at least one selected from the group consisting of inhibition of axonal elongation, the number of axonal collateral branches, and swimbladder dysplasia is evaluated.

8. A screening kit for a preventive or therapeutic drug for TDP-43 protein degeneration, comprising the zebrafish according to any one of claims 1 to 5.

9. A screening device for a preventive or therapeutic drug for TDP-43 protein degeneration, comprising: a zebrafish according to any one of claims 1 to 5; a well plate containing any one of the zebrafish; and a light irradiation device.

Citation Information

Patent Citations

  • Screening method of compound for therapy and / or prevention of TDP-43 agglomerate-accumulating disease

    JP2014171425A

  • Methods for screening compounds for treating and / or preventing diseases associated with TDP-43 agglomerate accumulation

    JP2018117638A

  • Optogenetic induction of neurodegenerative disease pathologies

    WO2018165293A1